Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation

Expert Review of Hematology

Volumn 5, Issue 4, 2012, Pages 409-425

  Bleakley, Marie ^a,b   Turtle, Cameron J ^a,c   Riddell, Stanley R ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

allogeneic transplantation; central memory; graft versus leukemia; immunotherapy; T cells

Indexed keywords

ACUTE LEUKEMIA; ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CELL FUNCTION; CELL SPECIFICITY; CELLULAR IMMUNITY; DONOR; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; PATIENT CARE; PRIORITY JOURNAL; REVIEW; STANDARD; TUMOR IMMUNITY;

CYTOKINES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; MINOR HISTOCOMPATIBILITY ANTIGENS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84866725832     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.28     Document Type: Review

References (173)

1. Gooley TA, Chien JW, Pergam SA et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 363(22), 2091-2101 (2010).
2. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3), 555-562 (1990).
3. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78(8), 2120-2130 (1991).
4. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3(7), 730-737 (1997).
5. + minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc. Natl. Acad. Sci. USA 96(15), 8639-8644 (1999).
6. Gao L, Xue SA, Hasserjian R et al. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation 75(9), 1429-1436 (2003).
7. Vago L, Perna SK, Zanussi M et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N. Engl. J. Med. 361(5), 478-488 (2009).
8. Molldrem J, Dermime S, Parker K et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88(7), 2450-2457 (1996).
9. Molldrem JJ, Clave E, Jiang YZ et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90(7), 2529-2534 (1997).
10. Molldrem JJ, Lee PP, Wang C et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6(9), 1018-1023 (2000).
11. + progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95(7), 2198-2203 (2000).
12. Andersen MH, Pedersen LO, Capeller B, Bröcker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 61(16), 5964-5968 (2001).
13. + T cells reactive to survivin antigen in patients with multiple myeloma. Clin. Cancer Res. 13(3), 1053-1060 (2007).
14. Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 97(9), 2903-2907 (2001).
15. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl. Acad. Sci. USA 97(9), 4796-4801 (2000).
16. Greiner J, Ringhoffer M, Taniguchi M et al. Receptor for hyaluronan acidmediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp. Hematol. 30(9), 1029-1035 (2002).
17. + T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 106(3), 938-945 (2005).
18. Giannopoulos K, Li L, Bojarska-Junak A et al. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int. J. Oncol. 29(1), 95-103 (2006).
19. + T cells specific for PRAME: a target for T-cell therapy. Clin. Cancer Res. 12(10), 3130-3136 (2006).
20. Quintarelli C, Dotti G, De Angelis B et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 112(5), 1876-1885 (2008).
21. + T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 113(10), 2245-2255 (2009).
22. Maecker B, Sherr DH, Vonderheide RH et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 102(9), 3287-3294 (2003).
23. Siegel S, Wagner A, Kabelitz D et al. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood 102(13), 4416-4423 (2003).
24. + T cells specific for human neutrophil elastase. Blood 103(8), 3076-3083 (2004).
25. Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15(17), 5323-5337 (2009).
26. Molldrem JJ, Lee PP, Kant S et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 111(5), 639-647 (2003).
27. Leisegang M, Wilde S, Spranger S et al. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J. Clin. Invest. 120(11), 3869-3877 (2010).
28. Pospori C, Xue SA, Holler A et al. Specificity for the tumor-associated self antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination. Blood 117(25), 6813-6824 (2011).
29. + T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102(8), 2892-2900 (2003).
30. + cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95(1), 286-293 (2000).
31. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59(11), 2675-2681 (1999).
32. Bornhäuser M, Thiede C, Platzbecker U et al. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood 117(26), 7174-7184 (2011).
33. ten Bosch GJ, Toornvliet AC, Friede T, Melief CJ, Leeksma OC. Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia 9(8), 1344-1348 (1995).
34. Clark RE, Dodi IA, Hill SC et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98(10), 2887-2893 (2001).
35. Padua RA, Larghero J, Robin M et al. PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat. Med. 9(11), 1413-1417 (2003).
36. Yotnda P, Garcia F, Peuchmaur M et al. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J. Clin. Invest. 102(2), 455-462 (1998).
37. Scholl S, Salzmann S, Kaufmann AM, Höffken K. Flt3-ITD mutations can generate leukaemia specific neoepitopes: potential role for immunotherapeutic approaches. Leuk. Lymphoma 47(2), 307-312 (2006).
38. + T cells. Blood 109(7), 2985-2988 (2007).
39. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surfaceimmunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327(17), 1209-1215 (1992).
40. Schuster SJ, Neelapu SS, Gause BL et al. Vaccination with patient-specific tumorderived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29(20), 2787-2794 (2011).
41. Osterroth F, Garbe A, Fisch P, Veelken H. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood 95(4), 1342-1349 (2000).
42. Pasqualucci L, Trifonov V, Fabbri G et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43(9), 830-837 (2011).
43. Trojan A, Schultze JL, Witzens M et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat. Med. 6(6), 667-672 (2000).
44. Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C. Adoptive transfer of minor histocompatibility antigenspecific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat. Med. 7(7), 789-794 (2001).
45. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat. Rev. Cancer 4(5), 371-380 (2004).
46. Bleakley M, Riddell SR. Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol. Cell Biol. 89(3), 396-407 (2011).
47. Reinsmoen NL, Kersey JH, Bach FH. Detection of HLA restricted anti-minor histocompatibility antigen(s) reactive cells from skin GVHD lesions. Hum. Immunol. 11(4), 249-257 (1984).
48. de Bueger M, Bakker A, Van Rood JJ, Van der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J. Immunol. 149(5), 1788-1794 (1992).
49. Niederwieser D, Grassegger A, Auböck J et al. Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versushost disease status and analyses of tissue distribution of their target antigens. Blood 81(8), 2200-2208 (1993).
50. Goulmy E, Gratama JW, Blokland E, Zwaan FE, van Rood JJ. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature 302(5904), 159-161 (1983).
51. Warren EH, Fujii N, Akatsuka Y et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 115(19), 3869-3878 (2010).
52. Spierings E, Hendriks M, Absi L et al. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genet. 3(6), e103 (2007).
53. Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92(5), 1549-1555 (1998).
54. Heslop HE, Slobod KS, Pule MA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115(5), 925-935 (2010).
55. Haque T, Wilkie GM, Jones MM et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a Phase 2 multicenter clinical trial. Blood 110(4), 1123-1131 (2007).
56. Bollard CM, Gottschalk S, Leen AM et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110(8), 2838-2845 (2007).
57. + Hodgkin's disease. J. Exp. Med. 200(12), 1623-1633 (2004).
58. Stanislawski T, Voss RH, Lotz C et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2(10), 962-970 (2001).
59. Ochi T, Fujiwara H, Okamoto S et al. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood 118(6), 1495-1503 (2011).
60. Johnson LA, Morgan RA, Dudley ME et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114(3), 535-546 (2009).
61. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126-129 (2006).
62. Heemskerk MH, Hoogeboom M, de Paus RA et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 102(10), 3530-3540 (2003).
63. Heemskerk MH, Hoogeboom M, Hagedoorn R, Kester MG, Willemze R, Falkenburg JH. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J. Exp. Med. 199(7), 885-894 (2004).
64. van der Veken LT, Hagedoorn RS, van Loenen MM, Willemze R, Falkenburg JH, Heemskerk MH. Alpha beta T-cell receptor engineered gamma delta T cells mediate effective antileukemic reactivity. Cancer Res. 66(6), 3331-3337 (2006).
65. Heemskerk MH, Hagedoorn RS, van der Hoorn MA et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 109(1), 235-243 (2007).
66. van Loenen MM, de Boer R, Hagedoorn RS, van Egmond EH, Falkenburg JH, Heemskerk MH. Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies. Haematologica 96(3), 477-481 (2011).
67. Ochi T, Fujiwara H, Yasukawa M. Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia. J. Biomed. Biotechnol. 2010, 521248 (2010).
68. Xue SA, Gao L, Thomas S et al. Development of a Wilms' tumor antigenspecific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica 95(1), 126-134 (2010).
69. van Loenen MM, de Boer R, Amir AL et al. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc. Natl. Acad. Sci. USA 107(24), 10972-10977 (2010).
70. Bendle GM, Linnemann C, Hooijkaas AI et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16(5), 565-70, 1p following 570 (2010).
71. Kuball J, Dossett ML, Wolfl M et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109(6), 2331-2338 (2007).
72. Bialer G, Horovitz-Fried M, Ya'acobi S, Morgan RA, Cohen CJ. Selected murine residues endow human TCR with enhanced tumor recognition. J. Immunol. 184(11), 6232-6241 (2010).
73. Sommermeyer D, Uckert W. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J. Immunol. 184(11), 6223-6231 (2010).
74. Scholten KB, Kramer D, Kueter EW et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin. Immunol. 119(2), 135-145 (2006).
75. Okamoto S, Mineno J, Ikeda H et al. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 69(23), 9003-9011 (2009).
76. Provasi E, Genovese P, Lombardo A et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18(5), 807-815 (2012).
77. van der Veken LT, Coccoris M, Swart E, Falkenburg JH, Schumacher TN, Heemskerk MH. Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo. J. Immunol. 182(1), 164-170 (2009).
78. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3(95), 95ra73 (2011).
79. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725-733 (2011).
80. + T cells derived from virus-specific central memory T cells. Blood 119(1), 72-82 (2012).
81. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22, 745-763 (2004).
82. + T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118(1), 294-305 (2008).
83. + T cells in immunodeficient mice. Blood 117(6), 1888-1898 (2011).
84. + T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. USA 106(41), 17469-17474 (2009).
85. + T cells do not induce graft-versus-host disease. J. Clin. Invest. 112(1), 101-108 (2003).
86. + T cells. Blood 115(23), 4923-4933 (2010).
87. Gattinoni L, Lugli E, Ji Y et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17(10), 1290-1297 (2011).
88. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174(5), 2591-2601 (2005).
89. Brentjens RJ, Rivière I, Park JH et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118(18), 4817-4828 (2011).
90. + T cell help. J. Exp. Med. 186(1), 65-70 (1997).
91. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333(16), 1038-1044 (1995).
92. Melenhorst JJ, Leen AM, Bollard CM et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 116(22), 4700-4702 (2010).
93. + T cells are defective in mediating acute graft-versushost disease but retain graft-versus-leukemia activity. Blood 103(10), 3970-3978 (2004).
94. Chen BJ, Cui X, Sempowski GD, Liu C, Chao NJ. Transfer of allogeneic CD62Lmemory T cells without graft-versus-host disease. Blood 103(4), 1534-1541 (2004).
95. Dutt S, Tseng D, Ermann J et al. Naive and memory T cells induce different types of graft-versus-host disease. J. Immunol. 179(10), 6547-6554 (2007).
96. Chen BJ, Deoliveira D, Cui X et al. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood 109(7), 3115-3123 (2007).
97. + T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood 111(4), 2476-2484 (2008).
98. André-Schmutz I, Le Deist F, Hacein-Bey-Abina S et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a Phase 1/2 study. Lancet 360(9327), 130-137 (2002).
99. Amrolia PJ, Muccioli-Casadei G, Yvon E et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 102(6), 2292-2299 (2003).
100. Solomon SR, Mielke S, Savani BN et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 106(3), 1123-1129 (2005).
101. Amrolia PJ, Muccioli-Casadei G, Huls H et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108(6), 1797-1808 (2006).
102. + regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood 110(5), 1689-1697 (2007).
103. Mielke S, Nunes R, Rezvani K et al. A clinical-scale selective allodepletion approach for the treatment of HLAmismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 111(8), 4392-4402 (2008).
104. McIver ZA, Melenhorst JJ, Grim A et al. Immune reconstitution in recipients of photodepleted HLA-identical sibling donor stem cell transplantations: T cell subset frequencies predict outcome. Biol. Blood Marrow Transplant. 17(12), 1846-1854 (2011).
105. Mielke S, McIver ZA, Shenoy A et al. Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies. Biol. Blood Marrow Transplant. 17(12), 1855-1861 (2011).
106. Di Stasi A, Tey SK, Dotti G et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365(18), 1673-1683 (2011).
107. Mielke S, Solomon SR, Barrett AJ. Selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy 7(2), 109-115 (2005).
108. Samarasinghe S, Mancao C, Pule M et al. Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy. Blood 115(2), 396-407 (2010).
109. Kasamon YL, Luznik L, Leffell MS et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol. Blood Marrow Transplant. 16(4), 482-489 (2010).
110. Luznik L, Bolaños-Meade J, Zahurak M et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 115(16), 3224-3230 (2010).
111. Luznik L, O'Donnell PV, Symons HJ et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 14(6), 641-650 (2008).
112. Leventhal J, Abecassis M, Miller J et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLAmismatched combined kidney and hematopoietic stem cell transplantation. Sci. Transl. Med. 4(124), 124ra28 (2012).
113. De Angelis B, Dotti G, Quintarelli C et al. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 114(23), 4784-4791 (2009).
114. Brewin J, Mancao C, Straathof K et al. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood 114(23), 4792-4803 (2009).
115. + stem cells. Mol. Ther. 14(2), 236-244 (2006).
116. Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat. Biotechnol. 20(1), 70-75 (2002).
117. Hoyos V, Savoldo B, Quintarelli C et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24(6), 1160-1170 (2010).
118. Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 16(9), 1035-1041 (2010).
119. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002).
120. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346-2357 (2005).
121. Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptormodified T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822-1826 (2011).
122. Parkhurst MR, Yang JC, Langan RC et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19(3), 620-626 (2011).
123. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18(4), 843-851 (2010).
124. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a Phase I clinical trial. Mol. Ther. 18(4), 666-668 (2010).
125. Straathof KC, Pulè MA, Yotnda P et al. An inducible caspase-9 safety switch for T-cell therapy. Blood 105(11), 4247-4254 (2005).
126. Bonini C, Bordignon C. Potential and limitations of HSV-TK-transduced donor peripheral blood lymphocytes after allo-BMT. Hematol. Cell Ther. 39(5), 273-274 (1997).
127. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276(5319), 1719-1724 (1997).
128. Tiberghien P, Ferrand C, Lioure B et al. Administration of herpes simplexthymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97(1), 63-72 (2001).
129. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107(6), 2294-2302 (2006).
130. Wang X, Chang WC, Wong CW et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118(5), 1255-1263 (2011).
131. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene 273(2), 141-161 (2001).
132. Inoue K, Ogawa H, Sonoda Y et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89(4), 1405-1412 (1997).
133. Scheibenbogen C, Letsch A, Thiel E et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100(6), 2132-2137 (2002).
134. Rezvani K, Yong AS, Savani BN et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 110(6), 1924-1932 (2007).
135. Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. USA 101(38), 13885-13890 (2004).
136. Rezvani K, Yong AS, Mielke S et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111(1), 236-242 (2008).
137. Keilholz U, Letsch A, Busse A et al. A clinical and immunologic Phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113(26), 6541-6548 (2009).
138. Ochsenreither S, Majeti R, Schmitt T et al. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood 119(23), 5492-5501 (2012).
139. Torikai H, Akatsuka Y, Miyauchi H et al. The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206. Bone Marrow Transplant. 40(2), 165-174 (2007).
140. den Haan JM, Meadows LM, Wang W et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279(5353), 1054-1057 (1998).
141. den Haan JM, Sherman NE, Blokland E et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268(5216), 1476-1480 (1995).
142. Pierce RA, Field ED, Mutis T et al. The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. J. Immunol. 167(6), 3223-3230 (2001).
143. de Rijke B, van Horssen-Zoetbrood A, Beekman JM et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J. Clin. Invest. 115(12), 3506-3516 (2005).
144. Akatsuka Y, Nishida T, Kondo E et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J. Exp. Med. 197(11), 1489-1500 (2003).
145. Kawase T, Nannya Y, Torikai H et al. Identification of human minor histocompatibility antigens based on genetic association with highly parallel genotyping of pooled DNA. Blood 111(6), 3286-3294 (2008).
146. Kawase T, Akatsuka Y, Torikai H et al. Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood 110(3), 1055-1063 (2007).
147. Warren EH, Vigneron NJ, Gavin MA et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 313(5792), 1444-1447 (2006).
148. Stumpf AN, van der Meijden ED, van Bergen CA, Willemze R, Falkenburg JH, Griffioen M. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. Blood 114(17), 3684-3692 (2009).
149. Armistead PM, Liang S, Li H et al. Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. PLoS ONE 6(8), e23217 (2011).
150. + CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. J. Exp. Med. 205(12), 2863-2872 (2008).
151. Dolstra H, Fredrix H, Maas F et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J. Exp. Med. 189(2), 301-308 (1999).
152. Dolstra H, de Rijke B, Fredrix H et al. Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes. Eur. J. Immunol. 32(10), 2748-2758 (2002).
153. Till BG, Jensen MC, Wang J et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112(6), 2261-2271 (2008).
154. James SE, Orgun NN, Tedder TF et al. Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood 114(27), 5454-5463 (2009).
155. James SE, Greenberg PD, Jensen MC et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J. Immunol. 180(10), 7028-7038 (2008).
156. Giordano Attianese GM, Marin V, Hoyos V et al. In vitro and in vivo model
157. Hombach A, Heuser C, Sircar R et al. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen. J. Immunother. 22(6), 473-480 (1999).
158. Shaffer DR, Savoldo B, Yi Z et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 117(16), 4304-4314 (2011).
159. Vera J, Savoldo B, Vigouroux S et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocytederived malignant cells. Blood 108(12), 3890-3897 (2006).
160. Hudecek M, Schmitt TM, Baskar S et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116(22), 4532-4541 (2010).
161. Pizzitola I, Agostoni V, Cribioli E et al. In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy. J. Immunother. 34(6), 469-479 (2011).
162. Nicholls S, Piper KP, Mohammed F et al. Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition. Proc. Natl. Acad. Sci. USA 106(10), 3889-3894 (2009).
163. Spierings E, Gras S, Reiser JB et al. Steric hindrance and fast dissociation explain the lack of immunogenicity of the minor histocompatibility HA-1Arg Null allele. J. Immunol. 182(8), 4809-4816 (2009).
164. Falkenburg JH, Goselink HM, van der Harst D et al. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J. Exp. Med. 174(1), 27-33 (1991).
165. van der Harst D, Goulmy E, Falkenburg JH et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 83(4), 1060-1066 (1994).
166. Kircher B, Stevanovic S, Urbanek M et al. Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br. J. Haematol. 117(4), 935-939 (2002).
167. Marijt WA, Heemskerk MH, Kloosterboer FM et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1-or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc. Natl. Acad. Sci. USA 100(5), 2742-2747 (2003).
168. Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia 18(4), 798-808 (2004).
169. Wilke M, Dolstra H, Maas F et al. Quantification of the HA-1 gene product at the RNA level; relevance for immunotherapy of hematological malignancies. Hematol. J. 4(5), 315-320 (2003).
170. Fujii N, Hiraki A, Ikeda K et al. Expression of minor histocompatibility antigen, HA-1, in solid tumor cells. Transplantation 73(7), 1137-1141 (2002).
171. Torikai H, Akatsuka Y, Yatabe Y et al. Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells: application for allogeneic transplantation. Int. J. Hematol. 87(5), 467-473 (2008).
172. Dickinson AM, Wang XN, Sviland L et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat. Med. 8(4), 410-414 (2002).
173. Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat. Med. 5(7), 839-842 (1999).